Studii clinice

1. CA124002 : *A phase II randomized non-comparative trial of irinotecan and carboplatin vs. Irinotecan in subjects 1-21 years of age with refractory solid tumors*
Sponsor: Bristol-Myers-Squibb Pharmaceutical Research Institute
An: 2003

2.20050197: *A Phase 2 Randomised, Double-blind, Placebo-controlled, Dose-finding Study of Darbepoetin alfa for the Treatment of Anemia in Pediatric Subjects with Solid Tumors Receiving Cyclic Chemotherapy*
Sponsor: Amgen Inc
An: 2008

3.SCH 717454: *A Study to Determine the Activity of SCH 717454 in Subjects with Osteosarcoma or Ewing's Sarcoma that has Relapsed after Standard Systemic Therapy*
Sponsor: Schering-Plough Research Institute
An: 2009

4.CA180-226 : *A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias resistant or Intolerant to Imatinib*
Sponsor: Bristol-Myers Squibb Company
An: 2011

5.OTR3001: *An Open-Label, Multucenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children from 6 to 16 Years Old, Inclusive, with Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgetics*
Sponsor: Purdue Pharma L.P.
An : 2011

7.PALO-10-20 : *A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.*
Sponsor: Helsinn Healthcare
An: 2012

8.KF5503-65: *A randomized, multi- site, open-label, active controlled, Phase II/III trial, evaluating the e fficacy and safety of Tapentadol oral solution assessing the morphine sparing effect in the treatment of severe postoperative pain in pediatric subjects aged from 3 years to less than 18 years old*
Sponsor: Grunenthal GMBH
An: 2013

9.NEUGR 005: *An Open Label, Randomized, Active Controlled, Dose Finding Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim at Doses of 300 µg/kg and 670 µg/kg in Pediatric Patients Diagnosed With Solid Tumors Receiving Chemotherapy*
Sponsor: Teva Pharmaceutical Industries
An: 2013

10.MK0517-029: *A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety and Tolerability of Fosaprepitant in Pediatric Patients for the prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated with Emetogenic Chemotherapy*
Sponsor: Merck Sharp &Dohme Corp
An: 2013

11. **XM02-*ONC-201*** *Multicenter, Open Label-Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of daily Subcutaneous Administration of 5 µg/kg tobo-filgrastim in Infants, Children and Adolescents with Solid Tumors without Bone Marrow Involvement".*

Sponsor: Teva Pharmaceutical Industries
An: 2014

12.CSTI571I2201: *A European Observational Registry Collecting Efficacy and Safety Data in Newly Diagnosed Pediatric Ph+ Acute Lymphoblastic Leukemia (ALL) Patients Treated with Chemotherapy + Imatinib With or Without HSCT*

Sponsor: Novartis
An: 2014